Company / Operating Cash Flow
Foghorn Therapeutics Inc. Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$100.4M
FY2025
5-year range
-$118.1M / $193.6M
FY2021-FY2025
Trend
+15.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 6 years, ranging from -$118M in FY2024 to $194M in FY2023.
Based on SEC 10-K filings.
-$100M in FY2025.
Declined from $194M to -$100M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 15.0% year-over-year.
- Peak operating cash flow was recorded in FY2023.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$100.4M | +15.0% |
| FY2024 | -$118.1M | -161.0% |
| FY2023 | $193.6M | +485.3% |
| FY2022 | -$50.3M | -60.6% |
| FY2021 | -$31.3M | +32.5% |
| FY2020 | -$46.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026